Market revenue in 2024 | USD 3,949.8 million |
Market revenue in 2030 | USD 7,565.5 million |
Growth rate | 11.2% (CAGR from 2025 to 2030) |
Largest segment | Biologics |
Fastest growing segment | PDE4 Inhibitors |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors, Biologics |
Key market players worldwide | Pfizer Inc, Sanofi SA, AbbVie Inc, Galderma Group AG Registered Shares, Eli Lilly and Co, Regeneron Pharmaceuticals Inc, Otsuka Holdings Co Ltd, Novartis AG ADR, Incyte Corp, LEO Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to atopic dermatitis drugs market will help companies and investors design strategic landscapes.
Biologics was the largest segment with a revenue share of 46% in 2024. Horizon Databook has segmented the Asia Pacific atopic dermatitis drugs market based on corticosteroids, calcineurin inhibitors, pde4 inhibitors, biologics covering the revenue growth of each sub-segment from 2018 to 2030.
The atopic dermatitis drugs market in Asia Pacific is driven by increasing emphasis on demand for better healthcare and improving economic status of countries. Among all regions, the market in this region is expected to exhibit the fastest CAGR of 14.1% during the forecast period.
Increase in pro-health initiatives, adoption of better treatments, and rise in consumer awareness are driving market growth in this region. In addition, rising prevalence of atopic dermatitis, increasing demand for cost-effective treatment, and growing population significantly contribute to market growth.
Asia Pacific markets, such as China, Australia, Korea, and Taiwan, already have healthcare reimbursement systems that provide inclusive coverage for molecular diagnostic tests. Major untapped opportunities in the form of unmet medical needs, increasing initiatives for scientific research, and positive economic growth are some of the primary growth drivers of this market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific atopic dermatitis drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific atopic dermatitis drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account